We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amicus Therapeutics, Inc. (FOLD - Free Report) reported fourth-quarter 2023 adjusted earnings of 1 cent per share against the Zacks Consensus Estimate of a loss of 6 cents. The company had reported a loss of 17 cents per share in the year-ago quarter.
The year-over-year improvement can be attributed to higher revenues of Galafold (migalastat) and the successful ongoing commercial launch of the newly approved Pombiliti + Opfolda.
Revenues in the fourth quarter totaled $115.1 million, up 31% year over year on a reported basis. The figure matched the Zacks Consensus Estimate. The top line comprised sales of Galafold, approved for Fabry disease and Pombiliti + Opfolda. On a constant-currency (cc) basis, total revenue growth was 27% year over year.
The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease in September 2023.
Shares of Amicus were down 6.5% on Feb 28 following the announcement of the earnings result. The stock has lost 4.3% in the past year compared with the industry’s decrease of 6.1%.
Image Source: Zacks Investment Research
Quarter in Detail
Galafold net product sales were $106.6 million in the fourth quarter, reflecting an increase of 18% year over year at cc. The drug’s sales were almost in line with our model estimate of $106.5 million.
Net product sales of Pombiliti + Opfolda were $8.5 million in the fourth quarter. The figure matched our model estimate. The commercial launch of the drug is currently underway in various markets, including Europe and the U.K.
As of Dec 31, 2023, Amicus had cash, cash equivalents and marketable securities worth $286.2 million compared with $280.3 million as of Sep 30, 2023.
Full-Year Results
In 2023, Amicus generated revenues of $399.4 million, increasing 20% year over year at cc.
In the same period, the company recorded an adjusted loss of 13 cents per share compared with a loss of 53 cents in 2022.
2024 Guidance
Amicus maintained the guidance it provided earlier in January 2024. The company continues to expect total Galafold revenue to grow in the range of 11-16% at cc.
This guidance reflects continued patient demand from both switch and treatment-naïve patients, expansion into other geographies, label extensions, continued diagnosis of new Fabry patients and commercial execution across all major markets, including the EU, Japan, the U.K. and the United States.
Amicus shares were down, probably because investors were not too impressed with the sales outlook.
Adjusted operating expenses are estimated in the band of $345-$365 million.
The company targets to achieve profitability on a non-GAAP basis for the full year of 2024. Also, FOLD is looking to generate over $0.5 billion in total revenues in 2024.
The company expects a non-GAAP profit in the first quarter of 2024 and the same is expected to build sequentially quarter-over-quarter thereafter.
Amicus is looking to ensure the successful global launches of Pombiliti and Opfolda in Pompe disease.
This apart, the company remains focused on advancing its ongoing label expansion studies in two rare diseases such as Fabry and Pompe disease.
Amicus Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for Indivior’s 2024 earnings per share have improved from $1.83 to $1.95. In the past year, shares of INDV have risen 12.6%.
Indivior’s earnings beat estimates in each of the trailing three quarters. INDV delivered an average earnings surprise of 48.06%.
In the past 60 days, the Zacks Consensus Estimate for Vanda Pharmaceuticals’ 2024 bottom line has improved from a loss of 46 cents per share to earnings of 1 cent. In the past year, shares of VNDA have plunged 30.4%.
Vanda Pharmaceuticals’ earnings beat estimates in each of the trailing three quarters. VNDA delivered an average earnings surprise of 92.88%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 69 cents to 71 cents. In the past year, shares of PBYI have risen 71%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Amicus Therapeutics, Inc. (FOLD - Free Report) reported fourth-quarter 2023 adjusted earnings of 1 cent per share against the Zacks Consensus Estimate of a loss of 6 cents. The company had reported a loss of 17 cents per share in the year-ago quarter.
The year-over-year improvement can be attributed to higher revenues of Galafold (migalastat) and the successful ongoing commercial launch of the newly approved Pombiliti + Opfolda.
Revenues in the fourth quarter totaled $115.1 million, up 31% year over year on a reported basis. The figure matched the Zacks Consensus Estimate. The top line comprised sales of Galafold, approved for Fabry disease and Pombiliti + Opfolda. On a constant-currency (cc) basis, total revenue growth was 27% year over year.
The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease in September 2023.
Shares of Amicus were down 6.5% on Feb 28 following the announcement of the earnings result. The stock has lost 4.3% in the past year compared with the industry’s decrease of 6.1%.
Image Source: Zacks Investment Research
Quarter in Detail
Galafold net product sales were $106.6 million in the fourth quarter, reflecting an increase of 18% year over year at cc. The drug’s sales were almost in line with our model estimate of $106.5 million.
Net product sales of Pombiliti + Opfolda were $8.5 million in the fourth quarter. The figure matched our model estimate. The commercial launch of the drug is currently underway in various markets, including Europe and the U.K.
As of Dec 31, 2023, Amicus had cash, cash equivalents and marketable securities worth $286.2 million compared with $280.3 million as of Sep 30, 2023.
Full-Year Results
In 2023, Amicus generated revenues of $399.4 million, increasing 20% year over year at cc.
In the same period, the company recorded an adjusted loss of 13 cents per share compared with a loss of 53 cents in 2022.
2024 Guidance
Amicus maintained the guidance it provided earlier in January 2024. The company continues to expect total Galafold revenue to grow in the range of 11-16% at cc.
This guidance reflects continued patient demand from both switch and treatment-naïve patients, expansion into other geographies, label extensions, continued diagnosis of new Fabry patients and commercial execution across all major markets, including the EU, Japan, the U.K. and the United States.
Amicus shares were down, probably because investors were not too impressed with the sales outlook.
Adjusted operating expenses are estimated in the band of $345-$365 million.
The company targets to achieve profitability on a non-GAAP basis for the full year of 2024. Also, FOLD is looking to generate over $0.5 billion in total revenues in 2024.
The company expects a non-GAAP profit in the first quarter of 2024 and the same is expected to build sequentially quarter-over-quarter thereafter.
Amicus is looking to ensure the successful global launches of Pombiliti and Opfolda in Pompe disease.
This apart, the company remains focused on advancing its ongoing label expansion studies in two rare diseases such as Fabry and Pompe disease.
Amicus Therapeutics, Inc. Price, Consensus and EPS Surprise
Amicus Therapeutics, Inc. price-consensus-eps-surprise-chart | Amicus Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Amicus currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Indivior PLC (INDV - Free Report) , Vanda Pharmaceuticals Inc. (VNDA - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Indivior’s 2024 earnings per share have improved from $1.83 to $1.95. In the past year, shares of INDV have risen 12.6%.
Indivior’s earnings beat estimates in each of the trailing three quarters. INDV delivered an average earnings surprise of 48.06%.
In the past 60 days, the Zacks Consensus Estimate for Vanda Pharmaceuticals’ 2024 bottom line has improved from a loss of 46 cents per share to earnings of 1 cent. In the past year, shares of VNDA have plunged 30.4%.
Vanda Pharmaceuticals’ earnings beat estimates in each of the trailing three quarters. VNDA delivered an average earnings surprise of 92.88%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 69 cents to 71 cents. In the past year, shares of PBYI have risen 71%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.